Bradley W. Christensen, MD


Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

Christopher Jean-Louis, DO, MPH


Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Joe Scandura, MD, PhD


Ruxolitinib in the Treatment of PV

Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.

Dickran G. Kazandjian, MD


Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Ira Braunschweig, MD


Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

M. Michele Blackwood, MD, FACS


Dr. Blackwood on the Implementation of the I SPY2 Trial in Breast Cancer

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

Jennifer M. King, MD


Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

University of Chicago Medicine


University of Chicago Medical Center Ranks Among Nation’s Best in 10 Specialties, According to U.S. News Survey

The University of Chicago Medical Center ranks among the nation’s best hospitals in 10 specialties, according to results of the U.S. News & World Report’s annual survey.

Amanda Cass, PharmD, BCPS, BCOP


Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Catherine Ann Shu, MD


NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Meghana Kesireddy, MBBS


Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Mojun Zhu, MD


Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Erminia Massarelli, MD, PhD, MS


Dr Massarelli on Addressing Unmet Needs in SCLC

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Neel P. Chudgar, MD


Beyond the Clinic: Leveraging Research to Tackle Lung Cancer Disparities

Lung cancer remains the most common cause of cancer death in the United States.

Tomer Mark, MD


Dr. Mark on ​Questions Regarding Sequencing in Multiple Myeloma

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

David Gerber, MD


Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer Care

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Puja S. Venkat


Dr. Venkat on Unmet Needs in Ovarian Cancer

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer. 

Yasir Y. Elamin, MD


Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Bilal A. Siddiqui, MD


Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Nitya Raj, MD,


Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Greg Nowakowski, MD, Mayo Clinic 


Exploring Emerging Data in DLBCL 

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Dario R. Roque, MD


Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Stephanie E. Weiss, MD, FASTRO


Dr. Weiss on Selecting Optimal Radiation Therapy for Brain Metastases

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Marilyn Huang, MD, MS


Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian Cancer

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

Brandon Mahal, MD


Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Bruce Feinberg, DO


The COVID-19 Pandemic Will Have Long-Term Impact on Oncology Practices

The COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.

Cleveland Clinic


Cleveland Clinic Opens New Cancer Center in Abu Dhabi

Cleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.

Eugenia Girda, MD


Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial Cancer

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Robert J. Lewandowski, MD, FSIR


HCC International Clinical Trials

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.